Vera Therapeutics, Inc. Class A Common Stock
VERA
$29.95
-7.07%
Vera Therapeutics is a clinical-stage biotechnology company focused on developing transformative treatments for serious immunological diseases, with its lead product candidate atacicept targeting autoimmune conditions like IgA nephropathy. The company occupies a niche position as a late-stage biotech with a potentially first-in-class therapy that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, offering a differentiated mechanism in the competitive renal immunology space. Investor attention is centered on the upcoming July 7 FDA decision for atacicept, which could catalyze a transition from a development-stage entity to a commercial-stage company, as highlighted by a recent $200 million fund bet on the stock. The narrative is driven by binary regulatory risk and the potential for significant value creation if the drug gains approval.…
VERA
Vera Therapeutics, Inc. Class A Common Stock
$29.95
Related headlines
VERA 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vera Therapeutics, Inc. Class A Common Stock's 12-month outlook, with a consensus price target around $81.79 and implied upside of +173.1% versus the current price.
Average Target
$81.79
0 analysts
Implied Upside
+173.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$43 - $125
Analyst target range
The stock is covered by 14 analysts, with a consensus recommendation of Strong Buy (mean 1.21 on a 1-5 scale). The average target price is $81.79, implying 92.4% upside from the current price of $42.50. The distribution shows 1 Neutral (Wedbush) and the rest Buy/Outperform, indicating strong bullish sentiment. The high target of $125.00 suggests potential for nearly 200% upside, likely assuming successful FDA approval and significant commercial uptake. The low target of $43.00 is just above the current price, reflecting a scenario where the drug is approved but with limited commercial success or delays. The wide spread between low and high ($43 to $125) indicates high uncertainty around the binary FDA decision. Recent ratings actions include multiple reaffirmations of Buy (Guggenheim, HC Wainwright, TD Cowen, BofA) and an upgrade from Peer Perform to Outperform by Wolfe Research in March 2026, signaling increasing confidence. The lone Neutral rating from Wedbush suggests some caution, but overall the analyst community is heavily bullish on the stock's prospects.
Bulls vs Bears: VERA Investment Factors
VERA presents a high-risk, high-reward binary opportunity centered on the July 7 FDA decision for atacicept. The bull case is supported by strong analyst conviction (92% upside to average target), impressive one-year price momentum (+83%), and a high short ratio that could fuel a squeeze on positive news. However, the bear case is equally compelling: zero revenue, accelerating losses (net loss of $121M in Q1 2026), and a valuation that is entirely speculative. The single most important tension is the FDA outcome—approval could send shares toward the $81.79 average target or higher, while a rejection could trigger a 55% decline to the 52-week low. Currently, the evidence slightly favors the bulls given the strong analyst consensus and recent positive momentum, but the risk is extreme.
Bullish
- 92% Upside to Analyst Target: The average analyst price target is $81.79, implying 92.4% upside from the current price of $42.50. With 14 analysts covering and a consensus Strong Buy rating (mean 1.21), the sell-side is overwhelmingly bullish on atacicept's approval and commercial potential.
- Strong Relative Strength Over 1 Year: VERA has gained 83.2% over the past year, vastly outperforming the S&P 500's 20.9% return. This sustained momentum reflects investor confidence in the lead drug candidate and the upcoming FDA decision.
- High Short Ratio Indicates Potential Squeeze: The short ratio is 7.83 days to cover, suggesting significant bearish positioning. A positive FDA decision could trigger a short squeeze, amplifying upside beyond fundamental targets.
- Strong Liquidity with Low Debt: The current ratio of 13.6 indicates ample short-term liquidity, and debt-to-equity is only 0.13, meaning the balance sheet is not overleveraged. This provides a cushion to fund operations through the FDA decision.
Bearish
- Zero Revenue and Deep Losses: VERA has no approved products and generated $0 revenue in Q1 2026, with a net loss of $121 million. The company is burning cash rapidly, with negative free cash flow of $106.7 million in the quarter.
- Binary FDA Risk on July 7: The stock's valuation hinges entirely on the July 7 FDA decision for atacicept. A rejection or delay could send shares down to the 52-week low of $19.07, a 55% decline from current levels.
- Negative Earnings and No Profitability Horizon: Trailing and forward P/E are both negative (-10.9 and -11.0), and the company is not expected to be profitable anytime soon. The PEG ratio is negative, indicating no earnings growth to justify the valuation.
- Elevated Price-to-Book Ratio: The price-to-book ratio of 5.4 is above the biotech industry average of 3-4x, suggesting investors are paying a premium for approval optionality. If the FDA decision disappoints, this premium could evaporate.
VERA Technical Analysis
The stock is in a strong uptrend over the past year, with a 1-year price change of +83.2%, significantly outperforming the S&P 500's +20.9% gain. Currently trading at $42.50, the stock sits at 63.5% of its 52-week range ($19.07 to $56.05), indicating it is in the upper half but not overextended near the highs. This positioning suggests sustained bullish momentum with room to run, though the recent pullback from the 52-week high of $56.05 warrants caution. Short-term momentum is mixed: the 1-month change is +24.1%, showing a sharp recovery from the June lows, while the 3-month change is only +0.6%, indicating a period of consolidation. The 1-month surge contrasts with the 6-month decline of -8.6%, suggesting a potential short-term reversal or mean reversion after a deeper correction. The stock's beta of 0.92 implies slightly lower volatility than the market, which is unusual for a biotech and may reflect its recent stabilization. Key support lies near the 52-week low of $19.07, while resistance is at the 52-week high of $56.05. A breakout above $56.05 would signal a resumption of the uptrend and target new highs, while a breakdown below $19.07 would negate the long-term bullish structure. The stock's volatility, as measured by beta, is near market levels, suggesting moderate risk for position sizing.
Beta
0.95
0.95x market volatility
Max Drawdown
-46.2%
Largest decline past year
52-Week Range
$19-$56
Price range past year
Annual Return
+46.5%
Cumulative gain past year
| Period | VERA Return | S&P 500 |
|---|---|---|
| 1m | -27.3% | +3.6% |
| 3m | -18.2% | +5.1% |
| 6m | -26.9% | +13.8% |
| 1y | +46.5% | +22.2% |
| ytd | -38.4% | +13.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VERA Fundamental Analysis
Vera Therapeutics is a pre-revenue clinical-stage biotech with zero revenue in the most recent quarter (Q1 2026), consistent with all prior quarters. The company has no approved products, so the growth trajectory is binary and tied to the FDA decision on atacicept. Research and development expenses were $86.0 million in Q1 2026, up from $41.3 million in Q1 2025, reflecting increased clinical trial activity. The company remains unprofitable, with a net loss of $121.0 million in Q1 2026, compared to a loss of $51.7 million in Q1 2025, as operating expenses have scaled. Gross margin is not applicable due to zero revenue, and the net margin is negative. The company's balance sheet shows a current ratio of 13.6, indicating strong short-term liquidity, with $114.4 million in cash as of Q1 2026. However, free cash flow was negative $106.7 million in Q1 2026, and the company has a debt-to-equity ratio of 0.13, suggesting low leverage. The negative free cash flow and reliance on equity financing (common stock issued $3.9 million in Q1 2026) indicate dependence on external capital to fund operations, with a cash runway that may require additional funding if the FDA decision is delayed or negative.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-293814000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VERA Overvalued?
Since net income is negative, we use the price-to-sales (PS) ratio, but revenue is zero, making PS undefined. Instead, we evaluate using EV/EBITDA, which is -10.2, reflecting negative EBITDA. The trailing PE is -10.9 and forward PE is -11.0, both negative due to losses. The gap between trailing and forward PE is negligible, implying no near-term profitability is expected. Compared to the biotechnology industry, Vera's negative multiples are typical for pre-revenue biotechs, but the stock trades at a premium based on market cap relative to peers with similar cash burn. The price-to-book ratio of 5.4 is elevated versus the industry average of around 3-4x, suggesting investors are paying a premium for the potential of atacicept. Historically, the PB ratio has ranged from 1.5x (Q2 2021) to 8.4x (Q3 2024), and the current 5.4x is near the midpoint, indicating the market is pricing in moderate optimism but not extreme euphoria. The stock's valuation is entirely driven by the probability of FDA approval, with no fundamental earnings support.
PE
-10.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-10.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Vera has no revenue and is deeply unprofitable, with a net loss of $121 million in Q1 2026, up 134% from $51.7 million in Q1 2025. The company burned $106.7 million in free cash flow in the quarter, and with only $114.4 million in cash, the cash runway is limited to roughly one quarter at the current burn rate. This creates a high risk of dilutive equity financing if the FDA decision is delayed or negative. The debt-to-equity ratio is low at 0.13, but the lack of revenue means the company is entirely dependent on external capital to survive.
Market & Competitive Risks: The stock's valuation is binary and tied to the FDA decision on atacicept. If approved, Vera will face competition from existing IgAN treatments like Tarpeyo (Calliditas) and Filspari (Travere), which have already established market share. The beta of 0.92 is low for a biotech, but the stock has shown high volatility around news events. A negative FDA decision would likely result in a severe valuation compression, as the current price-to-book of 5.4x is already above industry averages. The recent $200 million fund bet highlights institutional interest, but also increases the risk of a sharp reversal if sentiment shifts.
Worst-Case Scenario: The most damaging scenario is an FDA rejection or Complete Response Letter (CRL) for atacicept on July 7. This would likely send the stock to or below the 52-week low of $19.07, representing a 55% decline from the current price of $42.50. In this scenario, the company would need to raise capital at depressed prices, further diluting shareholders. The historical max drawdown of -43.85% suggests that severe declines are possible, and a rejection could exceed that, potentially reaching -60% or more if the drug's future is in doubt.